Protection against beta-amyloid induced abnormal synaptic function and cell death by Ginkgolide J

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease is characterized by amyloid-beta (Aβ) peptide aggregation.
• Aβ(1-42) is a primary toxic species implicated in Alzheimer's pathogenesis.
• Long-term potentiation (LTP) inhibition is a key indicator of synaptic dysfunction in Alzheimer's.

Purpose of the Study:

• To investigate the neuroprotective potential of a novel Ginkgo biloba extract (P8A, TTL) against Aβ(1-42) induced toxicity.
• To identify the specific component(s) responsible for the extract's neuroprotective effects.
• To evaluate the therapeutic promise of Ginkgo biloba components for Alzheimer's disease.

Main Methods:

• Preparation of Ginkgo biloba extract P8A (TTL), enriched to 70% in terpene trilactones.
• Assessment of Aβ(1-42) induced inhibition of long-term potentiation (LTP) in mouse hippocampal slices.
• Evaluation of Ginkgolide J's ability to replicate the extract's effects and inhibit Aβ(1-42) induced neuronal cell death.

Main Results:

• Ginkgo biloba extract P8A (TTL) prevented Aβ(1-42) induced inhibition of LTP in the CA1 region of mouse hippocampal slices.
• Ginkgolide J, a component of the extract, fully replicated the neuroprotective effect of P8A (TTL).
• Ginkgolide J demonstrated efficacy in inhibiting Aβ(1-42) induced cell death in rodent hippocampal neurons.

Conclusions:

• The Ginkgo biloba extract P8A (TTL) exhibits significant neuroprotective properties against Aβ(1-42) toxicity.
• Ginkgolide J is identified as a key active compound mediating the extract's beneficial effects.
• Ginkgolide J represents a promising therapeutic lead for the development of novel Alzheimer's disease treatments.